MTX 463
Alternative Names: MTX-463Latest Information Update: 08 Aug 2024
At a glance
- Originator Mediar Therapeutics
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action WISP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 07 Aug 2024 MTX 463 receives Fast Track designation for Idiopathic pulmonary fibrosis [Parenteral] (In volunteers) in USA
- 07 Aug 2024 MTX 463 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
- 17 May 2024 Pharmacodynamics and adverse events data from a preclinical trial in Fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)